China's NDRC Releases First Set Of Price Cuts; MNCs See Deepest Cuts As Expected
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - China's National Development and Reform Commission has released long-awaited price cuts that will mostly affect multinational pharma companies
You may also be interested in...
Asia Spotlight: GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
GSK’s Lamictal, Sanofi’s Lantus Among Latest Round Of China Price Cuts
China’s NDRC cuts retail ceiling prices on more than 700 formulations of 400 drugs across 20 therapeutic areas, targeting newer products.
Bristol’s Taxol, Sanofi’s Taxotere Among Latest Victims Of China Price Cuts
China’s NDRC cuts retail ceiling prices on 95 cancer, hematology and immunology drugs, with more cuts expected next year.